Board of Directors
Leif Håkansson has a background as a Assoc. Professor at Lund, University, Senior Consultant in Oncology and Head of Clinical Tumorology at the University Hospital in Linköping. Leif Håkansson received both his MD and PhD at Lund University and subsequently held various positions at both university hospitals in Linköping and Lund. Dr. Håkansson’s research includes immune parameters important for immune and biochemical therapy in various forms of cancer, p. a. kidney cancer, malignant melanoma and colon cancer Leif Håkansson has published more than 75 reviewed articles, held more than 40 conference presentations on the above and other topics and is the inventor of more than 10 approved patents. Leif Håkansson is, among other responsibilities, in the board of CDDF – the Cancer Drug Development Forum.
MBA, M.Sc. Formerly C.E.O of NeuroVive Pharmaceutical AB and G.M. of Schering-Plough AB. Has 30 years of drug industry experience, with several executive positions in marketing and corporate management.
Gregory Batcheller has a strong backgrond in emerging life science and pharmaceutical company development. He holds a JD from University of Toronto and a LLM from Lund University, Sweden. Greg is an accomplished dealmaker and has successfully negotiated many international licensing and M&A deals in Europe, the U.S., and China. Current assignmets are Chairman of the Board of Xintela AB, Saga Diagnostics AB, Monocl AB, Immune Biotech Medical Sweden AB and CarryGenes Therapeutics AB.
Lars Karlsson MD, PhD, has extensive experience in drug discovery and development from senior positions at Johnson & Johnson, Regulus Therapeutics, Novo Nordisk, Silence Therapeutics, and Ferring Pharmaceuticals. He has expertise in immunology, pharmacology and translational science.